Nektar Seeking New Partner For Exubera As Pfizer Returns Rights
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer pays Nektar $135 million, resolving Exubera contract, and returns rights – providing Nektar finds a partner, firm tells “The Pink Sheet” DAILY.